GIPERANDROJENIK SINDROMLI AYOLLARDA PERIMENOPOZ DAVRINING KLINIK KURSI
##article.subject##:
giperandrogenizm, gormonlar, tuxumdonlar, buyrak usti bezlari, reproduktiv kasalliklar##article.abstract##
Giperandrogenizm - androgenlarning ortiqcha ishlab chiqarilishi natijasida kelib chiqadigan endokrin holatning buzilishi. Bu sindrom tuxumdonlar va buyrak usti bezlarida androgen ishlab chiqarishning ko'payishining natijasidir. Ammo bu bo'linish juda o'zboshimchalik bilan amalga oshiriladi, chunki buyrak usti bezlarida androgen ishlab chiqarishning ko'payishi ularning tuxumdonlarda ko'payishiga olib kelishi mumkin va aksincha. Ayollarda androgenlar tuxumdonlar, buyrak usti bezlari va periferik to'qimalar tomonidan sintezlanadi, ular ham metabolizmda faol ishtirok etadi. Ayollarda ham, erkaklarda ham androgenlar to'plamiga dehidroepiandrosteron sulfat, dehidroepiandrosteron, androstenedion, testosteron va 5-alfa-dihidrotestosteron (5-alfa-DHT) kiradi, lekin erkaklardan farqli o'laroq, ayollarda oxirgi ikki gormonga qaraganda birinchi uchta gormonning konsentratsiyasi yuqori bo'ladi. . Ayollarda buyrak usti bezlarida androgenlarning sintezi adrenokortikotrop, tuxumdonlarda esa - luteinizing gormoni (LH), shuningdek, boshqa ba'zi intraglandulyar avtoparakrin mexanizmlari bilan tartibga solinadi. So'nggi tadqiqotlar tufayli androgenlarning asosiy biologik, ilgari ma'lum bo'lgan ta'siridan tashqari, ularning ayol tanasiga ta'sir qilishning yangi mexanizmlari kashf qilindi.
Библиографические ссылки
Brown D.L., Henrichsen T.L., Clayton A.C., Hudson S.B., Coddngton C.C., Vella A. Ovarian stromal hyperthecosis: sonographic features and histologic associations. J Ultrasound Med 2009; 28: 587—593.
Buggs C., Rosenfield R.L. Polycystic ovary syndrome in adolescence. Endocrinol Metabol Clin North Am 2005; 34: 677—705.
Cordera F., Grant C., van Heerden J., Thompson G., Young W. Androgensecreting adrenal tumors. Surgery 2003; 134: 874—880.
Davison S.L., Bell R., Donath S., Montalto J.G., Davis S.R. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metabol 2005; 90: 3847—3853.
Diamanti-Kandarakis E., Lambrinoudaki I., Economou F. Androgens associated with advanced glycation end-products in postmenopausal women. Menopause 2010; 17: 1182—1187.
Dorgan J.F., Stanczyk F.Z., Kahle L.L., Brinton L.A. Prospective case-control study of premenopausal serum estradiol and testosterone levels and breast cancer risk. Breast Cancer Res 2011; 12: R98.
Kaltsas G.A., Isidori A.M., Kola B.P. The value of the low-dosedexamethasone suppression test in the differential diagnosis of hyperandrogenism in women. J Clin Endocrinol Metabol 2003; 88: 2634—2643.
Klotz R.K., Muller-Holzner E., Fessler S. Leydig-celltumor of the ovary that responded to GnRH-analogue administration — case report and literature review. Exp Clin Endocrinol Diabetol 2010; 118: 291—297.
Krug E., Berga S.L. Postmenopausal hyperthecosis: functional dysregulation of androgenesis in the climacteric ovary. Obstet Gynecol 2002; 99: 893—897.
Martin K.A., Chang R.J., Ehrmann D.A., Ibanez L., Lobo R.A., Rosenfield R.L., Shapiro J., Montori V.N., Swiglo B.A. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metabol 2008; 93: 1105—1120.
Nieman L.K. Approach to the patient with an adrenal incidentaloma. J Clin Endocrinol Metabol 2010; 95: 4106—4113. 15. Norman R.J.D., Legro R.S., Hickey T.E. Polycystic ovary syndrome. Lancet 2007; 370: 685—697.
Rittmaster R.S. Polycystic ovary syndrome, hyperthecosis and the menopause. Clin Endocrinol (Oxford) 1997; 46: 129—130.
Rosner W., Auchus R.J., Azziz R., Sluss P.M., Raff H. Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metabol 2007; 92: 405—413.
Rothman M.S., Carlson N.E., Xu M. Reexamination of testosterone, dihydrotestosterone, estradiol and estrone levels across the menstrual cycle and in postmenopausal women measured by liquid chromatography-tandem mass spectrometry. Steroids 2011; 76: 177—182.
Rothman M.S., Wierman M.E. How should postmenopausal androgen excess be evaluated? Clin Endocrinol 2011; 75: 160—164.
Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41—47.
Shaw L.J., Bairey Merz C.N., Azziz R., Stanczyk F.Z., Sopko G., Braunstein G.D., Kelsey S.F., Kip K.E., Cooper-Dehoff R.H., Johnson B.D., Vaccarino V., Reis S.E. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health — National Heart, Lung, and Blood Institute sponsored Women’s Ischemia Syndrome Evaluation. J Clin Endocrinol Metabol 2008; 93: 1276—1284.
Speiser P.W., Azziz R., Baskin L.S., Ghizzoni L., Hensle T.W., Merke D.B. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metabol 2010; 95: 4133—4160.
Thompson G.B., Young W.F.Jr. Adrenal incidentaloma. Curr Opin Oncol 2003; 15: 84—90.
Waggoner W., Boots L.R., Azziz R. Total testosterone and DHEAS levels as predictors of androgen-secreting neoplasms: a populational study. Gynecol Endocrinol 1999; 13: 394—400.
Wild R.A., Carmina E., Diamanti-Kandarakis E., Dokras A., Escobar-Morreale H.F., Futterweit W., Lobo R., Norman R.J., Taibott E., Dumesic D.A. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metabol 2010; 95: 2038—2049.
Winters S.J., Talbott E., Guzick D.S., Zborowsky J., McHugh K.P. Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome. Fertil Steril 2000; 73: 724—729.
Yetkin D.O., Demirsoy E.T., Kadioglu P. Pure leydig cell tumour of the ovary in a post-menopausal patient with severe hyperandrogenism and erythrocytosis. Gynecol Endocrinol 2011; 27: 237—240.
